18KIT
Time for Type 2?
Dexcom CGM, AID and Type 2 Diabetes
At ATTD 2024* Dexcom
announced compelling
new clinical evidence
supporting the use
of Dexcom continuous glucose
monitoring (CGM) for automated
insulin delivery (AID) systems.
Dexcom also announced data
showcasing the significant benefits
of CGM use for individuals managing
Type 2 diabetes, along with groundbreaking
evidence demonstrating a
direct association between CGM use
and reduced mortality in people with
Type 1 and Type 2 diabetes.
Kevin Sayer, President, CEO, and
Chairman of the Board at Dexcom
said that, "The breadth of studies
and outcomes showcased here at
ATTD demonstrates the crucial role
that Dexcom CGM can play in the
treatment of Type 2 diabetes. As
the pioneer in biosensing, since last
year's ATTD, Dexcom has moved at
an extraordinary pace. We launched
G7 in 16 additional countries, released
Dexcom ONE+ and we've announced
the phased launch of 'Direct-towatch'**.
Globally, we've expanded
access to Dexcom products by over 5
million people."
Driving access
Dexcom launched its G7 sensor in 16
new markets since ATTD 2023. The
company's latest sensor, Dexcom
ONE+, was built based on user and
HCP feedback and is designed to
be easy to use for anyone living
with diabetes and was also recently
launched in four European markets.
Dexcom's pioneering capabilities
within connected systems remains
ahead of the field. Of particular
significance within AID systems, the
clinically meaningful health outcomes
resulting from use of both the
Tandem t:slim X2 insulin pump with
Control-IQ technology and Insulet
Omnipod 5 are only proven when
powered by Dexcom CGM.
Dexcom also announced the
availability, in the USA, of Dexcom
G6 with Tandem Mobi, the world's
smallest, durable automated insulin
delivery system++. Integration with
Dexcom G7 will quickly follow in
the USA in the second quarter of
this year.
Dexcom data also showed that
amongst Type 2 user populations, the
more regularly a Dexcom CGM was
worn, the more time a user spent
within their desired glucose range5.
Furthermore, a qualitative study
involving people treating their Type
2 diabetes with basal insulin found
the visualisation of glucose levels
offered by Dexcom CGM improved
understanding of the impact of
treatment and lifestyle decisions
on glucose levels, and the impact of
those glucose levels on additional
health issues6.
Dr Thomas Grace, MD, Head of
Clinical Advocacy and Outcomes
at Dexcom comments, "A range
of studies demonstrate the role
that Dexcom CGM can play in the
treatment of Type 2 diabetes. From
demonstrating a clinically significant
decrease in HbA1c to increasing time
in range and generally improving
well-being, the results speak for
themselves. We also continue to see
studies confirm that whilst GLP-1s
are an effective initial treatment for
those living with Type 2 diabetes
and the use of Dexcom CGM can
strengthen their impact and provide
an alternative for sustained longterm metabolic
health improvement."
*ATTD 2024: Advanced Technologies
and Treatments for Diabetes,
held March 6-9, 17th International
Conference.
**Direct-to-watch 'functionality
for Apple Watch will begin a phased
launch available to all G7 iOS users in
the second quarter of this year in the
US. It means Dexcom G7 CGM will be
the only one that connects directly
to Apple Watch without needing to
carry an iPhone. People choosing
Dexcom G7 to help manage their
diabetes will have access to 'direct to
Apple Watch' as soon as it launches in
their country. www.jdrf.org.uk